In the TITAN and ENZAMET trials, unprecedented overall survival outcomes were observed in patients with metastatic castration-sensitive prostate cancer receiving an agent targeting the androgen receptor in addition to androgen-deprivation therapy early in the course of their disease. Herein, I discuss both trials in the context of other studies in this disease setting.

中文翻译：

---

继续改善转移性前列腺癌男性的预后

在TITAN和ENZAMET试验中，对于转移性去势敏感性前列腺癌患者，在其病程早期接受了除雄激素治疗之外，还接受了靶向雄激素受体的药物，观察到了空前的总体生存结果。在此，我将在该疾病背景下的其他研究背景下讨论这两项试验。